Journal article
Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk
Ganna Chornokur, Hui-Yi Lin, Jonathan P Tyrer, Kate Lawrenson, Joe Dennis, Ernest K Amankwah, Xiaotao Qu, Ya-Yu Tsai, Heather SL Jim, Zhihua Chen, Ann Y Chen, Jennifer Permuth-Wey, Katja KH Aben, Hoda Anton-Culver, Natalia Antonenkova, Fiona Bruinsma, Elisa V Bandera, Yukie T Bean, Matthias W Beckmann, Maria Bisogna Show all
PLoS One | PUBLIC LIBRARY SCIENCE | Published : 2015
Abstract
BACKGROUND: Defective cellular transport processes can lead to aberrant accumulation of trace elements, iron, small molecules and hormones in the cell, which in turn may promote the formation of reactive oxygen species, promoting DNA damage and aberrant expression of key regulatory cancer genes. As DNA damage and uncontrolled proliferation are hallmarks of cancer, including epithelial ovarian cancer (EOC), we hypothesized that inherited variation in the cellular transport genes contributes to EOC risk. METHODS: In total, DNA samples were obtained from 14,525 case subjects with invasive EOC and from 23,447 controls from 43 sites in the Ovarian Cancer Association Consortium (OCAC). Two hundred..
View full abstractGrants
Awarded by NIH
Awarded by European Commission
Awarded by NCI Cancer Post-GWAS Initiative
Awarded by Ovarian Cancer Research Fund
Awarded by Canadian Institute of Health Research New Investigator Award
Awarded by NIEHS T32 training grant
Awarded by California Cancer Research Program
Awarded by Canadian Institutes of Health Research
Awarded by Cancer Research UK
Awarded by Danish Cancer Society
Awarded by Polish Ministry of Science and Higher Education
Awarded by US National Cancer Institute
Awarded by US Public Health Service
Awarded by National Health and Medical Research Council of Australia
Awarded by German Federal Ministry of Education and Research of Germany Programme of Clinical Biomedical Research
Awarded by State of Baden-Wurttemberg through Medical Faculty of the University of Ulm
Awarded by Lon V. Smith Foundation
Awarded by The Francis Crick Institute
Awarded by DIVISION OF CANCER CONTROL &POPULATION SCIENCE
Awarded by DIVISION OF CANCER PREVENTION AND CONTROL
Awarded by NATIONAL CANCER INSTITUTE
Awarded by NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
Awarded by NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES
Funding Acknowledgements
The scientific development and funding for this project were funded by the following: NIH R01 CA-1491429 (Phelan PI); the US National Cancer Institute (R01-CA076016); the COGS project is funded through a European Commission's Seventh Framework Programme grant (agreement number 223175 HEALTH F2 2009-223175); the Genetic Associations and Mechanisms in Oncology (GAME-ON): a NCI Cancer Post-GWAS Initiative (U19-CA148112); the Ovarian Cancer Association Consortium is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07). Investigator-specific funding: GCT is supported by the National Health and Medical Research Council; BK holds an ACS Early Detection Professorship (SIOP-06-258-01-COUN); LEK is supported by a Canadian Institute of Health Research New Investigator Award (MSH-87734). AWL is supported by NIEHS T32 training grant (T32ES013678). Funding of included studies: Funding of the constituent studies was provided by the California Cancer Research Program (00-01389V- 20170, N01-CN25403, 2II0200); the Canadian Institutes of Health Research (MOP-86727); Cancer Australia; Cancer Council Victoria; Cancer Council Queensland; Cancer Council New South Wales; Cancer Council South Australia; Cancer Council Tasmania; Cancer Foundation of Western Australia; the Cancer Institute of New Jersey; Cancer Research UK (C490/A6187, C490/A10119, C490/A10124); the Danish Cancer Society (94-222-52); the ELAN Program of the University of Erlangen-Nuremberg; the Eve Appeal; the Helsinki University Central Hospital Research Fund; Helse Vest; the Norwegian Cancer Society; the Norwegian Research Council; the Ovarian Cancer Research Fund; Nationaal Kankerplan of Belgium; Grant-in-Aid for the Third Term Comprehensive 10-Year Strategy For Cancer Control from the Ministry of Health Labour and Welfare of Japan; the L & S Milken Foundation; the Polish Ministry of Science and Higher Education (4 PO5C 028 14, 2 PO5A 068 27); the Roswell Park Cancer Institute Alliance Foundation; the US National Cancer Institute (K07-CA095666, K07-CA143047, K22-CA138563, N01-CN55424, N01-PC67001, N01-PC067010, N01-PC035137, P01-CA017054, P01-CA087696, P30-CA072720, P50-CA105009, P50-CA136393, R01-CA014089, R01-CA016056, R01-CA017054, R01-CA049449, R01-CA050385, R01-CA054419, R01-CA058598, R01-CA058860, R01-CA061107, R01-CA061132, R01-CA067262, R01-CA071766, R01-CA074850, R01-CA080742, R01-CA080978, R01-CA083918, R01-CA087538, R01-CA092044, R01-095023, R01-CA122443, R01-CA112523, R01-CA114343, R01-CA126841, R01-CA136924, R03-CA113148, R03-CA115195, U01-CA069417, U01-CA071966 and Intramural research funds); the US Army Medical Research and Material Command (DAMD17-01-1-0729, DAMD17-02-1-0666, DAMD17-02-1-0669, W81XWH-07-0449, W81XWH-10-1-02802); the US Public Health Service (PSA-042205); The National Health and Medical Research Council of Australia (199600 and 400281); the German Federal Ministry of Education and Research of Germany Programme of Clinical Biomedical Research (01GB 9401); the State of Baden-Wurttemberg through Medical Faculty of the University of Ulm (P.685); the Minnesota Ovarian Cancer Alliance; the Mayo Foundation; the Fred C. and Katherine B. Andersen Foundation; the Lon V.Smith Foundation (LVS-39420); the Oak Foundation; the OHSU Foundation; the Mermaid I project; the Rudolf-Bartling Foundation; the UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge, Imperial College London, University College Hospital "Womens Health Theme" and the Royal Marsden Hospital; WorkSafeBC 14.